Laurie Glimcher

Laurie Hollis Glimcher (born 1951) is an American physician-scientist and former President and CEO of Dana–Farber Cancer Institute.^[1] She was elected a member of the American Philosophical Society in 2019. Glimcher has been at the center of controversies related to animal rights activists,^[2] excessive corporate payments,^[3] and research misconduct.^[4] A 2021 investigation by the Boston Globe Spotlight team highlighted Glimcher’s activities on multiple corporate boards, including Bristol Myers Squibb, GlaxoSmithKline, and Analog Devices.^[5] After this investigation, Glimcher continued to receive compensation on for-profit boards, while doubling her salary to $4 million per year at Dana-Farber.^[6]

In October 2024, Glimcher stepped down as President and CEO of Dana-Farber because an investigation revealed falsified data in research papers she published.^[7][8]

Glimcher graduated from the Winsor School, an all-girls private school in Boston, Massachusetts, in 1968.^[9] In 1972, she graduated magna cum laude from Radcliffe College, and then graduated cum laude from Harvard Medical School in 1976.^[10]

She joined the board of directors of Bristol-Myers Squibb in 1997 and retired from the board in 2017.^[11][12][13] Her research laboratory received funding from Merck & Co for a project focused on developing new therapies for the treatment of osteoporosis in 2008.^[14]

From 1991 to 2012, Glimcher was the Irene Heinz Given Professor of Immunology at the Harvard School of Public Health, a professor of medicine at Harvard Medical School.^[15] Clinically, she is a specialist in osteoporosis.^[10][11]

From 2012 to 2016, Glimcher served as the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College and the Cornell University Provost for Medical Affairs.^[16][17]

In February 2016, Laurie Glimcher was named the President and CEO of Dana–Farber Cancer Institute. Glimcher was considered for the position for the Dean of Harvard Medical School but turned the position down in order to become the president of the Dana–Farber Cancer Institute.^[18]

At Dana-Farber, Glimcher collaborated on research to find methods of combatting cancer from within the human immune system.^[19] The Dana–Farber Cancer Institute is an institution that is affiliated with Harvard, as it currently is one of its teaching hospitals. Glimcher, who was the first female dean of any medical school in New York state, became the first female to lead the Dana–Farber Cancer Institute.^[20]

In 2017, she joined the board of GlaxoSmithKline.^[21] In 2020, she joined the board of Analog Devices.^[22]

Glimcher's research has focused on the immune system; she is known for early work with T cell differentiation, her discovery that Schnurri-3 regulates osteoblasts which led to a collaboration with Merck & Co., and her discovery of the role played by XBP-1 in lipogenesis and the unfolded protein response.^[23][24] Glimcher's role helped discover Schnurri-3 (Shn3 for short) is a large zinc finger protein distantly related to Drosophila. Shn is a potent and essential regulator of adult bone formation.^[25] Her research has had implications for understanding asthma, HIV, inflammatory bowel disease, and osteoporosis, and around 2016, on cancer immunotherapy.^[26]

Glimcher became interested in immunology during her first year of medical school at Harvard.^[27] There she took interest dysregulation in autoimmune diseases and, in her fourth year at Harvard, discovered the protein known as Nk1.1 (see natural killer T cell), which soon became widely recognized across the field of immunology.^[27] For this discovery, Glimcher became the first woman to receive the Soma Weiss Award, an honor her father had received 26 years earlier. During this time, Glimcher worked with mentor Bill Paul, who strongly encouraged her to continue her research independently after completing medical school.

Glimcher currently heads her own lab for research in immunology. She has been interested in studying the ties between ER stress system in neurons and immune function and neuro-degeneration.^[27] Her past work has involved regulation of immune function and has shifted towards osteobiology with a focus on the bone disease osteoporosis. Her Harvard lab has a three-year contract with Merck for the drug Fosamax, a treatment for osteoporosis.^[27] Glimcher's more current research looks to answer the question, “How does the immune system and the ER stress system impact cancer development and progression?”^[27]

Glimcher received the L'Oréal-UNESCO Awards for Women in Science in 2014 for her work in the field of immunology and her research regarding the control of immune responses.^[28][27] In 2014, she received the Margaret Kripke Legend Award.^[29] She received the Steven C. Beering Award in 2015.^[30] In 2018, she received the American Association of Immunologists Lifetime Achievement Award.^[31]

She has been elected to the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences and the American Philosophical Society. She is a member of American Academy of Arts and Sciences, American Association of Immunologists, American Society for Clinical Investigation, American Association of Physicians, and American Association for the Advancement of Science.^[16] She was the president of the American Association of Immunologists from 2003 to 2004.^[32]

In 2020 she was named the newest member of the Stand Up to Cancer Scientific Advisory Committee.^[33]

Glimcher is the daughter of Geraldine Lee (Bogolub) and Melvin J. Glimcher, who was a pioneer in the development of artificial limbs while the chair of the Massachusetts General Hospital Orthopedics Department. Her family is Jewish.^[34]

Glimcher followed in the footsteps of her father by later becoming a full professor at Harvard Medical School at the age of 39; the two became research partners.^[19]

She is married to Gregory Petsko, Professor of Neurology in the Ann Romney Center for Neurologic Diseases at Harvard Medical School and Brigham and Women's Hospital, who was director of the Rosenstiel Basic Medical Sciences Research Center and chair of biochemistry at Brandeis University prior to moving to Weill Cornell Medicine, where he became director of the Helen and Robert Appel Alzheimer's Disease Research Institute.^[35] Glimcher was previously married to Hugh Auchincloss,^[36] who is the top deputy to Dr. Anthony Fauci,^[37] and was a chief of Transplant Surgery at Brigham & Women's Hospital,^[38] and with whom she had three children, Kalah, Hugh and Jake Auchincloss.^[39]

Her daughter, Kalah Auchincloss, J.D., M.P.H., is a senior vice president of regulatory compliance and deputy general counsel for Greenleaf Health and previously was deputy chief of staff for two Food and Drug Administration commissioners.^[40]

Her eldest son, Dr. Hugh Glimcher Auchincloss, is also a physician, currently a cardiothoracic surgeon at Massachusetts General Hospital.^[41] Her younger son, Jake Auchincloss, is currently the Representative for the Massachusetts's 4th congressional district.^[37][42][43]

In 2015, Glimcher was targeted by animal rights activists over their protest of withdrawal of support for chimpanzees in Liberia by the New York Blood Center where Glimcher had been on the board for two years.^[2]

When Glimcher began work at Dana-Farber, she continued to serve on the board of pharmaceutical company Bristol Myers Squibb even though the company was involved in a legal battle with Dana-Farber over patent rights and drug royalties. She subsequently resigned from that position and joined another pharmaceutical board, as a director of GlaxoSmithKline. Glimcher's dual role as Dana-Farber CEO and as director of multiple corporate boards was highlighted in the Boston Globe Spotlight article "Boston’s hospital chiefs moonlight on corporate boards at rates far beyond the national level,"^[44] and resulted in multiple calls among Harvard physicians and Boston hospital staff for the prohibition of hospital executives from serving on corporate boards.^[45]

In January 2024 Glimcher was among four researchers at Dana-Farber accused of falsifying data in research papers. Images in the papers had been manipulated in a way that suggested deliberate attempts to mislead readers.^[7] She has attempted to correct some of the data, however six of these papers have been retracted pending outcome of investigation while others are being corrected.^[46][47]

• Dana-Farber Cancer Institute
• Scientific misconduct

• Official home page at Harvard